Heparin-induced thrombocytopenia

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 8, 2011, Pages 594-599

  Bambrah, Ramandeep K ^a   Pham, Dat C ^a   Zaiden, Robert ^a   Vu, Ho ^a   Tai, Shawn ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Anticoagulation; Deep vein thrombosis; Heparin induced thrombocytopenia

Indexed keywords

ARGATROBAN; FC RECEPTOR; FONDAPARINUX; HEPARIN; HIRULOG; IMMUNOGLOBULIN G; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; SEROTONIN;

ANEMIA; BLEEDING; DEEP VEIN THROMBOSIS; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; GOLD STANDARD; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; IMMUNOASSAY; NAUSEA; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEROTONIN RELEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION;

HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 80053078120     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a metaanalysis. Blood. 2005;106:2710-2715
2. Sadler JE, Mortimer P. Antibody-mediated thrombotic disorders: thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia. In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT. Williams Hematology. 8th ed. Stony Brook, NY: McGraw-Hill; 2010.
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335
4. Lopes RD, Ohman EM, Granger CB, et al. Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH. registry). Am J Cardiol. 2009;104:1285-1291
5. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost. 2003;1:1471-1478
6. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101:2955-2959
7. Creekmore FM, Oderda GM, Pendleton RC, Brixner DI. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy. 2006;26:1438-1445
8. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239
9. Thachil J. The prothrombotic potential of platelet factor 4. Eur J Intern Med. 2010;21:79-83
10. Shanberge JN, Quattrociocchi-Longe TM. Influence of platelet factor 4 on the neutralization of heparin by protamine. Ann N Y Acad Sci. 1989;556:354-365
11. Coutre S. Heparin-induced thrombocytopenia. www.uptodate.com. Accessed on January 2010.
12. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765
13. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30
14. Harenberg J, Huhle G, Giese C, et al. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2000;109:182-186
15. Legnani C, Cini M, Pili C, Boggian O, Frascaro M, Palareti G. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost. 2010;104:402-409
16. Pouplard C, Leroux D, Regina S, Rollin J, Gruel Y. Effectiveness of a new immune-assay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost. 2010; 103:145-150
17. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation. 1999;100:587-593
18. Lubenow N, Eichler P, Lietz T, Greinacher A; HIT Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005;3:2428-2436
19. Warkentin TE, Greinacher A, Koster A, Lincoff AM; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:340S-380S.
20. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparininduced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007;27:564-587
21. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation. 2003;108:2062-2065
22. Meera R, Rachel D, Ramakrishnapillai V, Vijayaraghavan G. Heparin induced thrombocytopenia management with bivalirudin. Indian Heart J. 2007;59: 354-355
23. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15:611-616
24. Saugel B, Phillip V, Moessmer G, Schmid RM, Huber W. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study. Crit Care. 2010;14:R90.
25. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2005;11:279-287
26. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812
27. Wallis DE, Quintos R, Wehrmacher W, Messmore H. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest. 1999; 116:1333-1338
28. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:311S-337S.
29. Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost. 2010;16:663-6677
30. Seldrum S, Lambert M, Hainaut P. Heparin-induced thrombocytopenia successfully treated with fondaparinux. Acta Clin Belg. 2009;64:144-146.